CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Boehringer Ingelheim Pharmaceuticals, Inc. recalls Synjardy XR Tablets…

Boehringer Ingelheim Pharmaceuticals, Inc. recalls Synjardy XR Tablets (empagliflozin and metformin hydrochloride exte…

Read the official FDA notice

Published
8 Jul 2026
Units affected
560 bottles
Agency
FDA
Country
United States

The hazard

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45

Brand / company
Boehringer Ingelheim Pharmaceuticals, Inc.
Codes / lots
Lot 3244413; Exp. 12/31/2028
Distribution
OH
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 8 Jul 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.